United Therapeutics CORP Form 4 insider transactions

Raymond Dwek, a director at United Therapeutics, acquired 2,890 stock options on July 25, 2024, as part of an annual non-employee director award.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales of common stock on July 23 and 24, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on July 19 and July 22, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on July 17 and 18, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on July 15 and 16, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales under a pre-arranged 10b5-1 trading plan.

Director Christopher Patusky reports acquisition of 900 shares of United Therapeutics common stock upon vesting of restricted stock units.

Director Judy D. Olian reports the vesting of restricted stock units and subsequent conversion into common stock of United Therapeutics.

Director Nilda Mesa reports the vesting of restricted stock units and subsequent conversion into common stock of United Therapeutics.

Director Ray Kurzweil reports the vesting of restricted stock units into common stock of United Therapeutics.

Director Richard Giltner reports the vesting of restricted stock units and subsequent conversion into common stock of United Therapeutics.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on July 9th and 10th, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on July 5th and July 8th, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales under a pre-arranged 10b5-1 trading plan on July 2nd and 3rd, 2024.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed multiple sales of common stock on June 28, 2024, and July 1, 2024, through a pre-arranged 10b5-1 trading plan.

Jan Malcolm, a new director at United Therapeutics, reports the acquisition of stock options and restricted stock units as part of the Non-Employee Director Compensation Program.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales under a pre-arranged 10b5-1 trading plan.

Director Tommy G. Thompson exercised stock options and sold shares of United Therapeutics Corp on June 26, 2024.

Director Nilda Mesa sold 266 shares of United Therapeutics Corp (UTHR) on June 25, 2024, at a price of $318.5784 per share.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on June 24 and 25, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on June 20 and 21, 2024, under a pre-arranged 10b5-1 trading plan.

Paul Mahon, EVP & General Counsel of United Therapeutics, reports exercising share tracking awards and disposing of common stock on June 20, 2024.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales of common stock under a pre-arranged 10b5-1 trading plan on June 17 and 18, 2024.

Christopher Causey, a director at United Therapeutics, exercised stock options and sold shares on June 18, 2024.

Director Judy D. Olian sold 1,700 shares of United Therapeutics Corp (UTHR) on June 17, 2024, at a price of $295.4267 per share.

Director Christopher Patusky reports the acquisition and disposal of United Therapeutics Corp (UTHR) common stock on June 17, 2024.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed a series of stock option exercises and sales on June 14, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, CEO of United Therapeutics, executed a stock option exercise and sale of common stock on June 13, 2024, under a pre-arranged 10b5-1 trading plan.

Christopher Causey, a director at United Therapeutics, exercised stock options and sold 2,000 shares of common stock on June 13, 2024.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on June 11 and 12, 2024, under a pre-arranged 10b5-1 trading plan.